Gashaw Yalewayker, Asmare Zelalem, Tigabie Mitkie, Sisay Asefa, Getatachew Ermias, Tadesse Selamyhun, Bitew Getachew, Ashagre Agenagnew, Misganaw Tadesse, Gashaw Muluken, Kassahun Woldeteklehaymanot, Dejazimach Zelalem, Jemal Abdu, Gedfie Solomon, Kumie Getinet, Nigatie Marye, Abebe Wagaw, Kidie Atitegeb Abera, Abate Biruk Beletew, Reta Melese Abate, Gelaw Baye
Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia.
Department of Medical Laboratory Science, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia.
BMC Infect Dis. 2025 Mar 29;25(1):437. doi: 10.1186/s12879-025-10826-5.
Antimicrobial resistance among Enterobacteriaceae poses a significant global threat, particularly in developing countries. Colistin, a critical last-resort treatment for infections caused by carbapenem-resistant and multidrug-resistant strains, is increasingly facing resistance due to inappropriate use of colistin and the spread of plasmid-mediated resistance genes. Despite the significance of this issue, comprehensive and updated data on colistin resistance in Africa is lacking. Thus, the current study was aimed to determine the pooled prevalence of colistin-resistant Enterobacteriaceae in Africa.
A systematic search was conducted across PubMed, Scopus, ScienceDirect, and Google Scholar to identify relevant studies. Forty-one studies reporting on the prevalence of colistin resistance in Enterobacteriaceae isolates from clinical specimens in Africa were included in the analysis. Stata 17 software was used to calculate the pooled prevalence of colistin resistance, employing a random-effects model to determine the event rate of resistance. Heterogeneity across studies was assessed using the I statistic, and publication bias was evaluated using Egger's test. Subgroup analyses were performed to address any identified heterogeneity.
This systematic review analyzed the colistin resistance profile of 9,636 Enterobacteriaceae isolates. The overall pooled prevalence of colistin resistance was 26.74% (95% CI: 16.68-36.80). Subgroup analysis by country revealed significant variability in resistance rates, ranging from 0.5% in Djibouti to 50.95% in South Africa. Species-specific prevalence of colistin resistance was as follows: K. pneumoniae 28.8% (95% CI: 16.64%-41.05%), E. coli 24.5% (95% CI: 11.68%-37.3%), Proteus spp. 50.0% (95% CI: 6.0%-106.03%), and Enterobacter spp. 1.22% (95% CI: -0.5%-3.03%). Analysis based on AST methods revealed significant differences in colistin resistance rates (p = 0.001). The resistance rates varied between 12.60% for the disk diffusion method and 28.0% for the broth microdilution method. Additionally, a subgroup analysis of clinical specimens showed significant variation (p < 0.001) in colistin resistance. Stool specimen isolates had the highest resistance rate at 42.0%, while blood specimen isolates had a much lower resistance rate of 3.58%.
Colistin resistance in Enterobacteriaceae is notably high in Africa, with significant variation across countries. This underscores the urgent need for effective antimicrobial stewardship, improved surveillance, and the development of new antibiotics.
肠杆菌科细菌的耐药性对全球构成重大威胁,在发展中国家尤为如此。黏菌素是治疗碳青霉烯耐药和多重耐药菌株引起感染的关键最后手段,但由于黏菌素使用不当和质粒介导耐药基因的传播,其耐药性日益增加。尽管这一问题很重要,但非洲缺乏关于黏菌素耐药性的全面和最新数据。因此,本研究旨在确定非洲耐黏菌素肠杆菌科细菌的合并流行率。
在PubMed、Scopus、ScienceDirect和谷歌学术上进行系统检索,以识别相关研究。分析纳入了41项报告非洲临床标本中肠杆菌科分离株黏菌素耐药率的研究。使用Stata 17软件计算黏菌素耐药的合并流行率,采用随机效应模型确定耐药事件发生率。使用I统计量评估研究间的异质性,并使用Egger检验评估发表偏倚。进行亚组分析以解决任何已识别的异质性。
本系统评价分析了9636株肠杆菌科分离株的黏菌素耐药情况。黏菌素耐药的总体合并流行率为26.74%(95%CI:16.68 - 36.80)。按国家进行的亚组分析显示耐药率存在显著差异,从吉布提的0.5%到南非的50.95%不等。黏菌素耐药的物种特异性流行率如下:肺炎克雷伯菌28.8%(95%CI:16.64% - 4 / 05%),大肠杆菌24.5%(95%CI:11.68% - 37.3%),变形杆菌属50.0%(95%CI:6.0% - 106.03%),肠杆菌属1.22%(95%CI: - 0.5% - 3.03%)。基于药敏试验方法的分析显示黏菌素耐药率存在显著差异(p = 0.001)。纸片扩散法的耐药率为12.60%,肉汤微量稀释法为28.0%。此外,对临床标本的亚组分析显示黏菌素耐药存在显著差异(p < 0.001)。粪便标本分离株的耐药率最高,为42.0%,而血液标本分离株的耐药率低得多,为3.58%。
非洲肠杆菌科细菌对黏菌素的耐药性显著较高,各国之间存在显著差异。这突出表明迫切需要有效的抗菌药物管理、加强监测以及开发新的抗生素。